Phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer.
Schab A, Compadre A, Drexler R, Loeb M, Rodriguez K, Brill J, Harrington S, Sandoval C, Sanders B, Kuroki L, McCourt C, Hagemann AR, Thaker P, Mutch D, Powell M, Serra V, Hagemann IS, Walts AE, Karlan BY, Orsulic S, Fuh KC, Sun L, Verma P, Lomonosova E, Zhao P, Khabele D, Mullen MM.
Schab A, et al. Among authors: thaker p.
J Clin Invest. 2025 May 20;135(13):e189511. doi: 10.1172/JCI189511. eCollection 2025 Jul 1.
J Clin Invest. 2025.
PMID: 40392598
Free PMC article.